Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 4/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264544 | 0.88 | L3MBTL1 (0.32) | NPSR1KDM4EALKGAAL3MBTL1 | |
| SCHEMBL2942781 | 0.87 | PTGDR2 (0.36) | KDM4EHPGDSMN1; SMN2ZAP70KARS1 | |
| SCHEMBL12415747 | 0.87 | TLR7 (0.34) | TLR7ZAP70KARS1ALKKMT2A | |
| SCHEMBL13236209 | 0.80 | PTGDR2 (0.47) | SMN1; SMN2 | |
| SCHEMBL13236218 | 0.80 | ALDH1A1 (0.37) | TLR7ZAP70KARS1GAAKMT2A | |
| SCHEMBL4333030 | 0.79 | KMT2A (0.34) | NPSR1KDM4EHPGDSMN1; SMN2ZAP70 | |
| SCHEMBL12568934 | 0.76 | NPSR1 (0.45) | NPSR1KDM4EHPGDSMN1; SMN2TLR7 | |
| SCHEMBL13264578 | 0.76 | ALK (0.30) | TLR7ZAP70KARS1ALKGAA | |
| SCHEMBL12415767 | 0.73 | ENPP1 (0.38) | GAAL3MBTL1KMT2AALDH1A1RAB9A | |
| SCHEMBL2944286 | 0.73 | PTGDR2 (0.48) | KDM4ESMN1; SMN2KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | NPSR1 655/4885KDM4E 4745/4885HPGD 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.